The Continuous Manufacturing from Batch: Can’t stop the future
The event organised by IMA Active division: dedicated to IMA's latest developments for oral solid pharmaceutical forms
Guia Bertuzzi (*), product manager at IMA Active: the IMA’s way from batch to manufacturing. This and the other conferences on the Continuous Manufacturing are available on demand at: https://ima.it/pharma/live-cant-stop-the-future/ (video: IMA)
Two days to discover IMA’s latest developments in the field of the Continuous Manufacturing. The “Can’t stop the future” conference was organised by the IMA Active division in the splendid setting of the Palazzo di Varignana, just outside Bologna, and at the IMA Active plant in Ozzano dell’Emilia.
IMA’s strong commitment to innovation and research
“We are very pleased to host numerous pharmaceutical customers from all over the world in the elegant structure of the Palazzo di Varignana and at one of the Group’s facilities” said Alberto Vacchi, IMA’s Chairman and CEO. (photo: IMA)
The event was dedicated to IMA’s latest developments in the field of Continuous Manufacturing of oral solid pharmaceutical forms with international guests from important bodies such as the MIT and the FDA and numerous pharmaceutical companies.
The two-day event (26 and 27 September) saw the participation of around 200 pharmaceutical customers from all over the world, in particular from EMEA, but also from the USA and the Far East, who expressed great interest in the latest developments in the Continuous Manufacturing.
The Continuous Manufacturing, the latest innovations in processing
A result that bears witness to IMA’s strong commitment to innovation and research into increasingly innovative solutions for the pharmaceutical sector.
On the second day, customers had a chance to see the latest innovations offered by IMA Active in pharmaceutical processing and Continuous Manufacturing at the plant of the division in Ozzano dell’Emilia.
The switch from Batch to Continuous Manufacturing could represent the most important evolution
The “Can’t stop the future” conference was organised by the IMA Active division in the splendid setting of the Palazzo di Varignana. (photo: Palazzo di Varignana Resort & SPA)
Solid dosage forms are still the most common, even though there have not been any significant changes in the last 50 years.
However, thanks to a number of pharmaceutical companies and encouragement from regulatory authorities, global companies have started to invest in Continuous Manufacturing.
The switch from Batch to Continuous Manufacturing could represent the most important evolution since the advent of the validation and qualification system. The objective of this conference was in fact to spell out the state of the art of Continuous Manufacturing.
Discussing with customers and their requests help give direction to strategic decisions
Alberto Vacchi, IMA’s Chairman and CEO. (photo: IMA)
The event was introduced by Alberto Vacchi, IMA’s Chairman and CEO, who said: “We are very pleased to host numerous pharmaceutical customers from all over the world in the elegant structure of the Palazzo di Varignana and at one of the Group’s facilities. For the IMA Group, the world of “Pharma”, with its increasingly demanding challenges, represents an extraordinary accelerator to which we are responding with a huge innovative effort in terms of digitization and automation. Discussing with our customers and hearing their requests helps give direction to our strategic decisions”.
Luca Cavazzini, Sales & Marketing Director of the IMA Active division, added the following comments: “We are very pleased to bring together pharmaceutical companies, regulatory authorities, academics and suppliers to talk about the accelerating process of adoption of Continuous Manufacturing for small molecules and biological products and collaboration between research groups worldwide to facilitate this process. This conference is an excellent opportunity for all of us to guide new technologies and new approaches in the pharmaceutical industry by improving quality, costs and service for the benefit of patients”.
Investment in R&D: the element of strong competitive advantage
Commitment to technological innovation has always been an element of strong competitive advantage for IMA: ongoing significant investment in R&D (around 4% of consolidated revenue) underlies the Group’s growth path and its ability to create value.
Suffice to say that the IMA Group owns more than 1,700 patents and patent applications in the world and has launched numerous new machine models over the last years.
Automatic machines for processing and packaging of pharmaceuticals, cosmetics, food, tea and coffee
Founded in 1961, IMA is a world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceuticals, cosmetics, food, tea and coffee. The Group has approximately 6,000 employees, of which approximately 2,400 abroad, and has 45 production plants in Italy, Germany, Switzerland, the United Kingdom, the United States, India, Malaysia, China and Argentina.
IMA has an extensive sales network consisting of 29 branches with sales and service in Italy, France, Switzerland, the United Kingdom, Germany, Austria, Spain, Poland, Israel, Russia, the United States, India, China, Malaysia, Thailand and Brazil, representative offices in Central and Eastern European countries and more than 50 agencies covering a total of approximately 80 countries. IMA S.p.A. has been listed on the Italian Stock Exchange since 1995 and in the STAR segment since 2001.
(*) Guia Bertuzzi, Product Manager at IMA Active
Guia Bertuzzi is Product Manager at IMA Active division since 2005. She has been working in mixing, granulation and powders handling systems for more than 20 years. She is expert in pharmaceutical engineering and process for Active Pharmaceutical Ingredients and Oral Solid Dosage forms.
